Mesenchymal and Hematopoietic Stem Cell Transplantation in Systemic Lupus Erythematosus

Anne E. Crosswell and Vincent S. Gallicchio
Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a complicated and largely unknown pathogenesis. Current treatments are effective for mild to moderate cases of SLE. However, severe refractory cases of SLE have a poor prognosis. The standard of care for advanced SLE can be harmful to the patient especially at high dosages for an extended period of time. Stem Cell therapy has the potential to be effective in treating mild to severe cases of SLE. Allogeneic Hematopoietic Stem Cells (HSC) and Mesenchymal Stem Cell transplantation (MSC) have both been shown to be beneficial for patients with refractory SLE. There are currently clinical trials for treatments using MSCs, HSCs, and MSC-enhanced HSCT (Hematopoietic Stem Cell Transplantation) to determine their efficacy in the treatment of SLE